GeoffreyJ.GorseMD

Infectious Disease • Saint Louis, MO

Professor, Internal Medicine, St Louis University School of Medicine

Join to view full profile

Dr. Gorse is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gorse's full profile

Already have an account?

Office
1225 S Grand Blvd
Saint Louis, MO 63104
Phone+1 314-577-8000

Fax+1 314-977-9196

Education & Training

University of California (Irvine)Fellowship, Infectious Disease, 1981 - 1983
University of California (Irvine)Fellowship, Infectious Disease, 1980 - 1981
University of California (San Francisco)/FresnoResidency, Internal Medicine, 1977 - 1980
David Geffen School of Medicine at UCLAClass of 1977

Certifications & Licensure

CA State Medical License 1978 - 2026
MO State Medical License 1989 - 2026
WV State Medical License 1983 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)
Completed
Phase 1
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine
Withdrawn
A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers
Completed
Phase 2
A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Completed
Phase 1
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Completed
Phase 1
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
Completed
Phase 1
Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults Start of enrollment: 2007 Apr 01
Completed
Phase 1
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly Start of enrollment: 2012 Oct 01
Withdrawn
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Preschool-Aged Household Contacts as a Risk Factor for Viral Respiratory Infections in Healthcare Personnel.
Zachary M Most, Ann-Christine Nyquist, Lewis J Radonovich, Maria C Rodriguez-Barradas, Connie Savor Price
Open Forum Infectious Diseases. 2023-02-01
1 citations
MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity o...
Geoffrey J Gorse, Stephen Grimes, Helen Buck, Hussain Mulla, Peter White
Vaccine. 2022-03-01
5 citations
A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
Geoffrey J Gorse, Stephen Grimes, Helen Buck, Hussain Mulla, Peter White
Vaccine. 2022-02-23

Press Mentions

Enhanced Flu Protection: Four Beats ThreeMarch 13th, 2015
Quadrivalent vs. Trivalent Flu Vaccines Comparing Responses to B StrainsMarch 13th, 2015